Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Wave Life soars on positive early data for WVE-006
US RNA medicines biotech Wave Life Sciences yesterday announced positive proof-of-mechanism data from the ongoing Phase Ib/IIa RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD),
Positive Outlook for Wave Life Sciences Driven by Promising RNA Editing Data and Strategic Opportunities
Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is
Wave stock soars 73% on positive data for RNA editing treatment (update)
Wave Life Sciences (NASDAQ:WVE) shares soared 38% in premarket trading Wednesday after the company announced positive proof-of-mechanism data from its Phase 1b/2a RestoraAATion-2 study for its therapy candidate WVE-006 in the treatment of alpha-1 antitrypsin deficiency,
Wave swells on first RNA editing data in humans
Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its stock even as the news also emerged that Takeda had pulled out of a Huntington's disease alliance with the biotech.
Promising Potential of WVE-006 in RNA Editing: Andrew Fein’s Buy Rating Supported by Positive Early Data
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE stock's potential in this $10B market.
Wave Life Sciences Stock Climbs on RNA Editing Progress
Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of patients with a genetic disorder that can lead to lung or liver disease. T
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.
Wave Life Sciences Shares Surge After RNA Editing Discovery
Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential life threatening and implicating the lungs and liver. As recently demonstrated in a Phase I and II concept trial,
Wave stock soars 66% on positive data for RNA editing treatment (update)
Wave Life Sciences (WVE) shares soared 66% after the company announced positive proof-of-mechanism data from a study of WVE-006 in the treatment of AATD. Read more here.
Wave Life Sciences: Buy Rating Affirmed on Promising RNA Editing Platform Data
Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The
Zacks.com on MSN
15h
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
Shares of Wave Life Sciences WVE surged 74.1% on Wednesday after the company reported positive proof-of-mechanism data from ...
1d
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing ...
FierceBiotech
1d
Wave hails first for human RNA editing with GSK-partnered prospect, sending stock skyward
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...
GEN
1d
Wave Clinical Trial Shows First Successful RNA Editing in Humans
Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...
biopharma-reporter
16h
Wave claims first clinical RNA editing title in rare genetic disease
Wave Life Sciences reports that it has successfully carried out RNA editing in two patients with alpha-1 antitrypsin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback